NCT04694846View on ClinicalTrials.gov

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

August 16, 2024

Study Completion Date

August 16, 2024

Conditions
Lung Non-Small Cell CarcinomaHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nicotine Replacement

Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges

DRUG

Bupropion Hydrochloride Controlled-release

Given PO

DRUG

Varenicline

Given PO

OTHER

Tobacco Cessation Counseling

Receive counseling

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Quality of Life Assessment

Ancillary studies

OTHER

Best Practice

Receive standard treatment

Trial Locations (2)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy, Philadelphia

19148

Jefferson Health, Methodist Hospital, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER

NCT04694846 - Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | Biotech Hunter | Biotech Hunter